Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) combines biopharmaceutical innovation with advanced technology solutions, focusing on cell therapy platforms and AI-driven operational strategies. This page serves as the definitive source for tracking the company’s latest developments across both sectors.
Investors and industry observers will find timely updates on clinical trial progress, strategic partnerships, and technology initiatives. Key content categories include cell therapy research milestones, AI/blockchain integration updates, financial disclosures, and acquisition announcements.
Our curated news collection enables stakeholders to monitor COEP’s progress in treating cancer and autoimmune diseases while tracking its expansion into automation and decentralized technologies. Bookmark this page for streamlined access to press releases and third-party analyses that matter to your investment strategy.
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings (NASDAQ: COEP), has entered into a licensing agreement with Monarch Therapeutics to enhance their SNAP-CAR NK cell therapy platform in oncology. The agreement provides SNAP Biosciences access to Monarch's small molecule adaptor technology, which enables SNAP-CAR cells to be directed by small molecule-based adaptors.
The integration of Monarch's technology with SNAP-CAR NK cells allows for simultaneous targeting of multiple tumor antigens and real-time activity modulation, addressing challenges like tumor heterogeneity and antigen escape. Under the agreement terms, Monarch will receive an upfront payment, potential development milestone payments, and royalties on net sales.
NUBURU (NYSE: BURU) has filed a $100 million SEC Registration Statement to support its strategic acquisition plans and blue laser technology business relaunch. The company is awaiting Italian government 'Golden Power' approval to acquire a defense and security business hub, which includes a DefenseTech Business and a SaaS Business component.
The acquisitions are expected to generate over $50 million in revenue for 2025, pending U.S. GAAP accounting and closing date. The regulatory assessment under Italy's \"golden power\" review is anticipated to conclude by the end of June. Additionally, NUBURU is implementing a Transformation Plan focusing on AI and robotics adoption through a partnership with COEPTIS' NexGenAI Affiliates Network.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a definitive merger agreement with Z Squared Inc., a Dogecoin mining company. The merger will transform Coeptis into the largest publicly-traded, Dogecoin-focused mining company globally. Under the agreement, Z Squared will become a wholly-owned subsidiary of Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.
The transaction, expected to close in Q3 2025, will involve Coeptis spinning out its biopharmaceutical operations while maintaining its technology operations. Post-merger, the company will be rebranded as Z Squared, Inc. and continue listing on Nasdaq. The combined entity will focus on mining Dogecoin (DOGE), which currently has a market cap exceeding $20B.
The new leadership team will include David Halabu as CEO and Michelle Burke as COO, while current Coeptis CEO Dave Mehalick will exit the Board upon closing. The merger is subject to shareholder approval, regulatory clearances, and continued Nasdaq listing requirements.
COEPTIS (NASDAQ: COEP) has announced a strategic partnership with NexGenAI Solutions Group to establish a new co-working technology hub in India, operated by Ishvara Tech Consulting LLP. The facility will focus on advancing AI, blockchain technologies, digital transformation, and robotic solutions for defense and security.
The hub features a 60-seat capacity (expandable to 100) and includes executive cabins, conference rooms, and modern amenities. This expansion follows COEPTIS' recent acquisition of the NexGenAI Affiliates Network platform and new contracts totaling $2.3 million, including a $600,000 deal with NUBURU.
Key initiatives include:
- Research & Development
- AI Marketing Strategy Execution
- Crypto Strategy Execution & blockchain applications
- Product & Service Expansion
- Development and integration of the NXG Token
NUBURU (NYSE: BURU) announces a strategic corporate update focused on two key business lines. The company is revitalizing its blue-laser technology business unit through a new strategic plan targeting defense sector applications, marked by a recent Joint-Pursuit Agreement.
The company is finalizing the acquisition of a Defense & Security Hub, expected to generate over $50 million in 2025 revenue, subject to approvals. This hub will deliver defense products and security solutions through a SaaS model.
As part of its Transformation Plan, NUBURU has formed a strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP) for AI and robotics solutions. The company has also invested in Supply@ME Capital Plc (LON:SYME), a fintech platform for inventory monetization. NUBURU has eliminated 100% of its long-term debt and is finalizing remaining payables with a strategic funding partner.
Coeptis Therapeutics (NASDAQ: COEP) has secured exclusive worldwide rights to develop and commercialize the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, expanding from its previous co-development rights. The company has formed GEAR Therapeutics, a majority-owned subsidiary, to advance GEAR-modified natural killer cells (GEAR-NK) into human trials.
The GEAR-NK technology represents a novel cancer treatment approach, allowing modified NK cells to be used alongside monoclonal antibodies (mAbs) without being neutralized - a common limitation in current treatments. The platform also shows potential for modifying hematopoietic stem cells to improve bone marrow transplant outcomes in hematological malignancies.
The technology was licensed from VyGen-Bio, Inc., with research origins at Sweden's Karolinska Institutet. According to Dr. Evren Alici, COEP Scientific Advisory Board member, pre-clinical proof-of-concept data suggests GEAR-NK could reduce NK cell fratricide while improving clinical benefits in treatments like CD38 mAbs for multiple myeloma.
COEPTIS (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network (NexGen) and NUBURU (NYSE: BURU), a blue laser technology company. The collaboration is part of NUBURU's Transformation Plan, led by Executive Chairman Alessandro Zamboni, focusing on defense-tech, security, and operational resilience solutions.
NexGen will support NUBURU by implementing AI-driven capabilities and robotic process automation to enhance marketing strategies and B2B sales processes, particularly in the defense and security sector. NUBURU aims to leverage its laser-technology expertise and recent investments to enable growth across its subsidiaries and strategic ventures.
The partnership will utilize NexGen's advanced platform, which employs AI algorithms and data analytics to optimize marketing strategies and enhance customer engagement. NUBURU's strategy involves positioning itself as a blitz-scaling enabler through the adoption of exponential technologies.
NUBURU (NYSE: BURU), a high-power industrial blue laser technology company, has announced a strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP) as part of its comprehensive Transformation Plan. The initiative, led by Executive Chairman Alessandro Zamboni, aims to enhance operational efficiency and revamp the company's business model.
The Transformation Plan focuses on leveraging NUBURU's blue-laser technology expertise while pursuing strategic acquisitions and commercial alliances. The partnership with NextGen will specifically target the enhancement of marketing and B2B sales processes, particularly in the defense and security sector, where NUBURU sees significant growth opportunities.
NextGen's platform will contribute advanced AI algorithms and data analytics to optimize marketing strategies and enhance customer engagement. This collaboration represents a key step in NUBURU's strategy to position itself as a tech and business growth enabler for its future subsidiaries and strategic ventures.
COEPTIS (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and Arketyp Valu, a developer within the Verus Project ecosystem. The collaboration aims to integrate NexGenAI's digital marketing solutions into the upcoming ValuSocial platform, leveraging Verus Coin's blockchain technology and Public Blockchains as a Service (PBaaS).
The Verus Project, which has recently achieved a market capitalization exceeding $500 million, will provide the foundation for ValuSocial's fully immersive environment. The platform will enable users to launch targeted digital campaigns combining marketing strategies with blockchain technology, facilitating engagement through digital tokens.
Nicholas Lyons, CEO of Arketyp Valu, and Dave Mehalick, CEO of COEPTIS, both expressed enthusiasm for the partnership, highlighting its potential to create a decentralized digital ecosystem that delivers value to users and businesses globally.
Coeptis (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and MarketLeverage, combining AI technology with performance-based marketing strategies. The collaboration connects NexGenAI's AI-powered platform with MarketLeverage's network of 5,500 advertisers and 55,000 publishers.
The partnership provides access to AI-driven campaign management, predictive analytics, and automated outreach capabilities. NexGenAI's platform enables affiliates to earn commissions through automated content distribution, social media sharing, and targeted email campaigns with real-time AI optimization.
The artificial intelligence marketing market is projected to grow from $27.83 billion in 2024 to $106.54 billion in 2029, with a CAGR of 31.6%. This partnership aims to enhance marketing efficiency, drive higher-quality traffic, and increase conversions through advanced automation and data-driven insights.
FAQ
What is the current stock price of Coeptis Therapeutics (COEP)?
What is the market cap of Coeptis Therapeutics (COEP)?
